FATTY ACIDS AS BIOCOMPONDS: THEIR ROLE IN HUMAN METABOLISM, HEALTH AND DISEASE – A REVIEW.
PART 2: FATTY ACID PHYSIOLOGICAL ROLES AND APPLICATIONS IN HUMAN HEALTH AND DISEASE

Lefkothea-Stella Kremmyda, Eva Tvrzicka*, Barbora Stankova, Ales Zak

Charles University in Prague, 1st Faculty of Medicine, 4th Department of Medicine, Czech Republic
E-mail: eva.tvrzicka@lf1.cuni.cz

Received: April 13, 2011; Accepted with revision: October 4, 2011

Key words: Fatty acids/Lipid mediators/Gene expression/Development/Cardiovascular/Cancer/Immunity

Background. This is the second of two review parts aiming at describing the major physiological roles of fatty acids, as well as their applications in specific conditions related to human health.

Results. The review included the current literature published in Pubmed up to March 2011. In humans, fatty acids are a principle energy substrate and structural components of cell membranes (phospholipids) and second messengers. Fatty acids are also ligands of nuclear receptors affecting gene expression. Longer-chain (LC) polyunsaturated fatty acids (PUFA), including eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and arachidonic acid are precursors of lipid mediators such as eicosanoids (prostaglandins, leukotrienes, thromboxanes), resolvins and neuroprotectins. Lipid mediators produced by EPA and DHA (LC n-3 PUFA; mainly found in oily fish) are considered as inflammation-resolving, and thus, fish oil has been characterised as antiinflammatory. Recommendations for EPA plus DHA intake from oily fish vary between 250-450 mg/day. Dietary reference values for fat vary between nutrition bodies, but mainly agree on a low total and saturated fat intake. The existing literature supports the protective effects of LC n-3 PUFA (as opposed to n-6 PUFA and saturated fat) in maternal and offspring health, cardiovascular health, insulin sensitivity, the metabolic syndrome, cancer, critically ill patients, and immune system disorders.

Conclusion. Fatty acids are involved in multiple pathways and play a major role in health. Further investigation and a nutrigenomics approach to the effects of these biocompounds on health and disease development are imperative and highlight the importance of environmental modifications on disease outcome.

INTRODUCTION

Fatty acid (FA) intake in the form of dietary fat has increased over the past forty years with the introduction of a more westernised lifestyle1,2. This dietary modification reflects also changes in the type of fat consumed towards increased consumption of saturated animal fat and lower intake of unsaturated fat (plant and marine sources) (ref.3). These dietary changes, along with others including decreased intake of antioxidants, vitamins, and minerals, in combination with environmental and lifestyle changes (pollutants, smoking, decreased physical activity levels), may play a detrimental role in human physiology, altering health and disease outcomes.

This review consists of two parts. Regarding biosynthesis, dietary sources, biological roles of fatty acids and lipid classes please refer to Part 1 of this review4. Fatty acids can be desaturated endogenously up to the Δ9 position due to lack of certain enzymes in humans. For this reason linoleic (LA; 18:2n-6) and α-linolenic (ALA; 18:3n-3) acids must be taken from the diet and are termed essential FA (EFA). Further elongation and desaturation of these FA to produce long-chain (LC) polyunsaturated FA (PUFA), including eicosapentaenoic (EPA; 20:5n-3), docosahexaenoic (DHA; 22:6n-3) and arachidonic acids (AA; 20:4n-6), is possible but not very efficient in humans. Thus, these FA may be characterised as conditionally essential depending on EFA availability. Genetic variation in human desaturase genes affects FA metabolism, plasma lipid profiles, and risk of disease development5-7. Recommendations for minimum dietary intake of EPA plus DHA vary between 250-450 mg/day8, especially for pregnant women and those of reproductive age. Rich sources of LC n-3 PUFA are fish oils and the flesh of oily fish, whereas non-oily (white) fish contain them but in lower amounts.

Long-chain PUFA with 18-20 carbon atoms, including EPA and AA, are precursors of eicosanoids (prostaglandins, leucotrienes and thromboxanes), which have a broad scale of regulatory, autocrine and paracrine effects. Long-chain PUFA with 20 and 22 carbon atoms are precursors of autacoids – resolvins (resolution phase interaction products), lipoxins and neuroprotectins9. FA are also ligands of nuclear receptors which take part in the subcellular control of metabolic pathways. Covalent modification of proteins by FA acylation enables their incorporation into membranes. Hydroxy FA are activators of some nuclear factors and are responsible for the expression of proinflammatory cytokines (interleukin (IL)-1, IL-6, IL-8, tumour necrosis factor (TNF)-α) and adhesion molecules (intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1).
These actions of FA and the lipid mediators produced exhibit the significance of FA for human metabolism and are reviewed in the present (second) part of this review. Various studies from current literature highlighting the physiological roles of FA and practical implications for health and disease, including maternal and offspring health, growth and development, EFA deficiency, oxidative stress, cardiovascular health, the metabolic syndrome, cancer, critically ill patients, and immune system disorders will be discussed here.

PHYSIOLOGICAL ROLES OF FATTY ACIDS

In humans, FA have a number of physiological roles as: energy substrates, structural and functional components of cell membranes, precursors for lipid mediators, components affecting signal transduction pathways and gene transcription. These roles will be presented in the following paragraphs.

Fatty acids as energy substrates

Fatty acids in the form of triacylglycerols (TAG) from dietary fat are a principal source of energy. Compared to proteins and carbohydrates they have about twice as much energy value and their storage in adipose tissue needs less amount of water. Around 25-35% of total energy intake (TEI) in humans comes from dietary fat, which is equivalent to an intake of 56-78 g of fat per day for a standard 8400 kJ (2000 kcal) diet. However, as fat intake has increased within recent years in western-type environments, this amount can be as high as 40-45% of TEI depending on food sources and habitual consumption. The energy value of LC FAs and very long chain FA (VLCFA) is 38 kJ/g (9 kcal/g), and that of medium chain FAs is 29 kJ/g (7 kcal/g). Short chain FAs represent an energy source for enterocytes and colonocytes. Fatty acids take part in transferring and depositing important lipid soluble molecules (such as vitamins A, D, E and K) and are precursors of lipid mediators (discussed below). Therefore, nutritional recommendations have been established regarding total fat and different types of fat, including EFA and LC n-3 PUFA. These will be presented below under the section entitled ‘Fatty acids in health and disease’.

Structural role of fatty acids

a. Isolators

Tissues with high content of TAG, such as subcutaneous and visceral fat, serve as temperature (e.g. in marine mammals like seals) and mechanical isolators. Moreover, VLCFA are structural components of ceramides, which decrease skin permeability to water and prevent its losses. A characteristic example is the presence of VLCFA in secretions of the Meibomian glands, where they serve as a barrier between tear film and skin lipids, preventing excessive evaporation of tears. Neural tissues contain insulating lipids which cover the neurones. The thicker the myelin layer, the faster the signal conduction along the axon.

b. Cell membrane structure

Fatty acids in the form of phospholipids are the structural components of all cell membranes. Their profile influences the thickness and fluidity of the membrane and, thus, the activity of membrane associated proteins (enzymes, ion channels, receptors and transporters) (ref.10). Phospholipid molecules include a hydrophilic ‘head’ (choline, ethanolamine, serine, inositol) connected through phosphoric acid to a hydrophobic part (one or two FA molecules). This enables the special arrangement of the lipid bilayer which incorporates hydrophobic molecules on the inner part of the membrane, and hydrophilic molecules on the outer part. Membrane stability is increased by the presence of specific molecules, such as cholesterol and specific proteins; the higher the content of these molecules, the lower the membrane fluidity. An additional factor that influences membrane fluidity is the degree of FA unsaturation. Unsaturated membrane FAs mainly have double bonds in cis configuration and each double bond results in approximately 60° folding of the hydrocarbon chain. As a result, FA chains occupy greater space which increases membrane fluidity. In contrast, saturated FAs (SFA) or unsaturated FAs in trans configuration, whose chains are straight and take up less space, decrease membrane fluidity. Notably, increasing the degree of unsaturation for a given phospholipid content influences membrane fluidity less than increasing phospholipid content itself (e.g. phospholipid : cholesterol or phospholipid : proteins ratio) (ref.9).

The lipoprotein cover has a similar structure to the cell membrane. It also contains phospholipids, cholesterol, and specific proteins which are called apolipoproteins. The polar heads of phospholipids are orientated toward the surface of lipoproteins and this enables lipoprotein solubility in plasma. The hydrophobic FA chains are orientated toward the core of the particle which is composed of cholesterol esters (CE) and TAG. Lipoprotein membrane fluidity increases in the following order: high density lipoproteins (HDL) < low density lipoproteins (LDL) < very low density lipoproteins (VLDL) (ref.11).

c. Second messenger chemical structure

Phosphatidylinositol (PI) and phosphatidylcholine (PC) may act as sources of intracellular signals in response to extracellular signals which interact with receptors on the outer layer of plasma membrane. Hormones, or other extracellular signals, bind to the plasma membrane receptor which leads to activation of phospholipase (PL) C (ref.15). Phospholipase C hydrolyses PI 4,5-bisphosphate (PIP2) releasing inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DG). In consequence, IP3 (which is water soluble) causes release of calcium (Ca2+) from the endoplasmic reticulum. The combination of DG (which is lipid soluble and stays bound to the plasma membrane) and increased levels of Ca2+ lead to activation of the enzyme protein kinase C (PKC). This enzyme catalyses the phosphorylation of some cellular proteins, affecting cellular responses to the initial extracellular trigger (hormone) (ref.16). Fatty acids originating from the sn-2 glycerol carbon of PC influence the activity of sec-
An extracellular signal binds with a plasma membrane receptor which in turn activates the enzymes PLD and PLA2. This results in production of phosphatidic acid (PA), though the enzymatic action of PLD on PC, which is later metabolised to DG. This leads to PKC activation. PC is also hydrolysed by PLA2 to free FA (FFA) and lyso-PC (LPC) which can potentially promote PKC activation and influence cellular responses.

Fatty acids as precursors of lipid mediators

Fatty acids of the cell membrane are precursors of lipid mediators, with eicosanoids (prostaglandins, PG; thromboxanes, TX; leukotrienes, LT) being one of the most important. They are called eicosanoids because they are formed by ‘precursor’ FA which contain 20 carbon atoms (from the Greek “eikosi” = twenty). Specifically, PUFA derived from the sn-2 glycerol carbon of cell membrane phospholipids, namely AA and EPA, are precursors of a number of eicosanoids. Other FAs such as DHA, docosapentaenoic acid (DPA; 22:5n-3), LA and Mead acid (20:3n-9) are precursors of various other lipid mediators as shown in (Table 1). Prostaglandin and TX synthetases, enzymes which catalyze the first step in a pathway leading through endoperoxides (PGG2 and PGH2) to prostacycline, PG, and TX, consist of a cyclooxygenase (COX) and a hydroperoxidase. Fatty acids are released from the cell membrane with the aid of PLA2 and transformed by COX type 1 and 2 to PG and TX, by lipoxygenase (LOX) type 5, 8, 12 and 15 to LT, hydroxyeicosatetraenoic (HETE), hydroperoxyeicosatetraenoic (HPETE), and hydroxyeicosapentaenoic (HEPE) acids. Also, recently found are trihydroxy-derivatives of EPA which are termed E-series resolvins (Rv) or lipoxins (LX), as well as dihydroxy- and trihydroxy-derivatives of DHA including D-series Rv (ref.15,16), protectins (docosatetraenes) or neuroprotectins (NP) (ref.17,18), and maresins (MaR). These have been termed specialised pro-resolving mediators (SPM) since they are involved in the clearance and regulation of inflammatory substances. Numbers in the PG and TX shorthand notation represent the number of double bonds in the molecule; the double bonds can be used for formation of cyclic- or oxy-derivatives.

Eicosanoids are rudimentary hormones or regulating molecules that appear in most organisms. Unlike endocrine hormones, which travel in the blood stream, eicosanoids have autocrine or paracrine actions. They alter the activity of the cells from which they were synthesised and of adjoining cells by binding to 7-transmembrane- helix (7-TM) receptors. Prostaglandins stimulate inflammation, regulate blood flow to particular organs, control ion transport across membranes, and modulate synaptic transmission. Thromboxanes are vasoconstrictors and potent hypertensive agents which also facilitate platelet aggregation. They are named after their role in clot formation (thrombosis). Thromboxane A2, produced by activated platelets, has prothrombotic properties, stimulating activation of new platelets as well as platelet aggregation. Lipoxygenase catalyses the initial step of the pathway leading to LT. Their name reflects the fact that they were
<table>
<thead>
<tr>
<th>FA</th>
<th>Enzyme</th>
<th>Initial products</th>
<th>Further products</th>
<th>Final products</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>AA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>COX</td>
<td>PG-s2: PGG2, PGH2</td>
<td>PGD2, PGE2, PGJ2, PGF2α, PGJ2</td>
<td>TX-s2: TXA2, TXB2</td>
<td>proinflammatory (highly potent)</td>
</tr>
<tr>
<td></td>
<td>15-LOX</td>
<td>15-HPETE</td>
<td>15-HETE</td>
<td>LXA4, LXB4</td>
<td>proinflammatory</td>
</tr>
<tr>
<td></td>
<td>12-LOX</td>
<td>12-HPETE</td>
<td>12S-HETE (12S-hydroxy-5Z,8Z,14Z-eicosatrienoic acid)</td>
<td>-</td>
<td>inactive?</td>
</tr>
<tr>
<td></td>
<td>12R-HETE (12R-hydroxy-5Z,8Z,14Z-eicosatrienoic acid)</td>
<td>-</td>
<td>NFκB activation ICAM-I, protooncogene expression</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5-LOX</td>
<td>5-HPETE</td>
<td>5-HETE, LTA4</td>
<td>LT-s4: LTB4, LTC4, LTD4, LTE4</td>
<td>proinflammatory</td>
</tr>
<tr>
<td></td>
<td>8-LOX</td>
<td>8-HPETE</td>
<td>8-HETE</td>
<td>-</td>
<td>proinflammatory</td>
</tr>
<tr>
<td></td>
<td>cyt P450 monooxygenases</td>
<td>by hydroxylases: 19-HETE, 20-HETE</td>
<td>-</td>
<td>-</td>
<td>proinflammatory</td>
</tr>
<tr>
<td></td>
<td>by epoxygenases: 5,6-EET</td>
<td>8,9-EET, 11,12-EET, 14,15-EET</td>
<td>5,6-epoxy-PGE1 diHETEs</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>COX</td>
<td>PG-s3: PGG3, PGH3</td>
<td>PGD3, PGE3, PGJ3</td>
<td>TX-s3: TXA3</td>
<td>proinflammatory (less potent)</td>
</tr>
<tr>
<td></td>
<td>15-LOX</td>
<td>15-HPEPE</td>
<td>15-HEPE (15-hydroxy-5,8,11,13,17-EPA)</td>
<td>-</td>
<td>antiinflammatory</td>
</tr>
<tr>
<td></td>
<td>12-LOX</td>
<td>12-HPEPE</td>
<td>12-HEPE</td>
<td>-</td>
<td>antiinflammatory?</td>
</tr>
<tr>
<td></td>
<td>5-LOX</td>
<td>5-HPEPE</td>
<td>5-HETE, LTA5</td>
<td>LT-s5: LTB5, LTC5, LTD5, LTE5</td>
<td>proinflammatory (less potent)</td>
</tr>
</tbody>
</table>
Table 1. Lipid mediators from different fatty acids and their functions. (continued).

<table>
<thead>
<tr>
<th>FA</th>
<th>Enzyme</th>
<th>Initial products</th>
<th>Further products</th>
<th>Final products</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>15-LOX</td>
<td>17SHPDHA</td>
<td><strong>Docosatrienes/protectins</strong>: NPD1 (10R,17S-dihydroxy-4Z,7Z,11E,13E,15Z,19Z-docosahexaenoic acid)</td>
<td>-</td>
<td>neutron protection, photoreceptor protection, protection from oxidative stress</td>
</tr>
<tr>
<td>DHA</td>
<td>5-LOX</td>
<td>17SHPDHA</td>
<td><strong>17S-D-series resolvins</strong>: 17S-RvD1 (7S,8,17-trihydroxy-4Z,9E,13Z,15E,19Z-DHA) (also D2-D6)</td>
<td>-</td>
<td>pro-resolving</td>
</tr>
<tr>
<td></td>
<td>Aspirin-inhibited-COX-2</td>
<td>17RHPDHA</td>
<td><strong>17R-D-series resolvins</strong>: 17R-RvD1 (also D2-D6)</td>
<td>-</td>
<td>pro-resolving</td>
</tr>
<tr>
<td></td>
<td>12-LOX</td>
<td>14-s-HPDHA</td>
<td><strong>Maresins</strong>: MaR1 (7,14S-dihydroxy-4Z,8E,10E,12Z,16Z,19Z-DHA)</td>
<td>-</td>
<td>pro-resolving</td>
</tr>
<tr>
<td>n-3 DPA</td>
<td>5,12,15-LOX</td>
<td>n-3 mono- and dihydroxy-DPA</td>
<td>-</td>
<td>pro-resolving?</td>
<td></td>
</tr>
<tr>
<td>Mead acid (20:3 n-9)</td>
<td>COX</td>
<td>PG-s1, TX-s1, LT-s3</td>
<td>-</td>
<td>proinflammatory</td>
<td></td>
</tr>
<tr>
<td>LA</td>
<td>9-LOX</td>
<td>9-HODE (9S-hydroxy-10,12-octadecadienoic acid)</td>
<td>-</td>
<td>ICAM1 expression</td>
<td></td>
</tr>
</tbody>
</table>

AA, Arachidonic acid; COX, Cyclooxygenase; cyt, Cytochrome; DHA, Docosahexaenoic acid; DPA, Docosapentaenoic acid; EET, Epoxyeicosatrienoic acid; EPA, Eicosapentaenoic acid; epi, Epimer; FA, Fatty acid; GST, Glutathione transferase; HEPE, Hydroxyeicosapentaenoic acid; HETE, Hydroxyeicosatetraenoic acid; HPEPE, Hydroperoxyeicosapentaenoic acid; HPETE, Hydroperoxyeicosatetraenoic acid; I/VCAM, Interleukin/ Vascular cell adhesion molecule; LA, Linoleic acid; LOX, Lipoxygenase; LT, Leukotriene; LX, Lipoxin; NFκB, Nuclear factor kappa B; NP, Neuroprotectin; PG, Prostaglandin; PPAR, Peroxisome proliferator-activated receptor; Rv, Resolvin; s(1-5), Series; TX, Thromboxane.
first found in leukocytes and contain three conjugated double bonds.

Acetylsalicylic acid (Aspirin), an anti-inflammatory and antithrombotic drug, as well as other non-steroidal anti-inflammatory drugs (NSAID), irreversibly stop the synthesis of eicosanoids, thus affecting many signalling pathways. Stopping eicosanoid synthesis results in the wide-range effects that NSAID have on inflammation, fever, pain, and blood clotting. An endogenous eicosanoid called anandamide (arachidonylethanolamide) can specifically bind to cannabinoid receptors (CB); CB1 is expressed in the brain, gastrointestinal tract and adipose tissue, whereas CB2 is expressed in cells of the immune system.

The effect of lipid mediators produced is very much dependent on their FA substrate. Different eicosanoids are produced from AA and EPA and these have different, often opposing, actions. Arachidonic acid is the precursor of 2-series PG and 4-series LT, whereas EPA is the precursor of 3-series PG and 5-series LT. The AA-derived PG and LT are synthesised in response to injury or stress, whereas the EPA-derived PG and LT appear to modulate the effects of 2-series PG and 4-series LT (usually on the same target cells). Eicosapentaenoic acid-derived PG is formed at a slower rate and attenuates the effects of excessive levels of AA-derived PG. Adequate production of these seems to protect against heart attack and stroke as well as certain inflammatory diseases such as arthritis, lupus, and asthma. The suppression of n-6 PUFA-derived eicosanoid production by n-3 PUFA may be caused by their competition for a common enzyme in the eicosanoid biosynthetic pathway, Δ6-desaturase. Also, EPA, through its mono- and trihydroxy-derivatives, decreases the production of proinflammatory cytokines (e.g. IL-1β, TNF-α). Consequently, EPA-derived eicosanoids are considered to be less inflammatory potent than those derived from AA, and this is one of the main reasons that fish oil (containing EPA but also DHA) has been derived from AA and EPA and these have different, often opposing, actions. Arachidonic acid is the precursor of 2-series PG and 4-series LT, whereas EPA is the precursor of 3-series PG and 5-series LT. The AA-derived PG and LT are synthesised in response to injury or stress, whereas the EPA-derived PG and LT appear to modulate the effects of 2-series PG and 4-series LT (usually on the same target cells). Eicosapentaenoic acid-derived PG is formed at a slower rate and attenuates the effects of excessive levels of AA-derived PG. Adequate production of these seems to protect against heart attack and stroke as well as certain inflammatory diseases such as arthritis, lupus, and asthma. The suppression of n-6 PUFA-derived eicosanoid production by n-3 PUFA may be caused by their competition for a common enzyme in the eicosanoid biosynthetic pathway, Δ6-desaturase. Also, EPA, through its mono- and trihydroxy-derivatives, decreases the production of proinflammatory cytokines (e.g. IL-1β, TNF-α). Consequently, EPA-derived eicosanoids are considered to be less inflammatory potent than those derived from AA, and this is one of the main reasons that fish oil (containing EPA but also DHA) has been characterised as having antiinflammatory properties.

Fatty acids and lipoperoxidation

Spontaneous reactions of the FA chain with molecular oxygen are studied because of the possible involvement of reaction products in destructive biological processes. Auto-oxidative processes result in a number of compounds (e.g. hydroperoxides). Fatty acids with two or more double bonds give rise to cyclic products. These compounds are not stable and, through hydroxyderivatives, they form stable compounds with carbonyl groups. Some of these compounds are used as markers of oxidative stress.

Linoleic acid, EPA, Mead acid (20:3n-9) and DHA may be substrates for lipoperoxidation. Specific markers of LA lipoperoxidation are 9- and 13-hydroxyoctadecanoic acids (9-HODE and 13-HODE), 2,4-dienone 13-oxooctadec-9,11-dienoic acid (13-OXO) and 13-hydroxyoctadecenoic acid (13-HPDOE). The latter is a significant component of oxidised LDL cholesterol and a more potent activator of nuclear factor kappa B (NFkB) than 13-HODE.

Products of non-enzymatic oxidation of AA and other 20 carbon atom FA (isoprostanes) are used as surrogate markers of oxidative stress. Other cyclic products are formed from ALA, EPA and DHA, so-called neuroprostanes. The formation of non-cyclic structures termed isoketals has been also described.

Fatty acid role in protein acylation

Acylation of proteins is an important covalent modification of proteins. It enables them to become incorporated into biological membranes and thus increase their structural stability, protein-to-protein interactions, as well as their catalytic activity. Modified proteins fulfill a number of functions in the organism. There are two pathways of protein acylation:

1) co-translational irreversible acylation catalysed by N-myristoyl transferase, and
2) post-translational reversible thioesterification of cysteine, which is not directly related to protein production and is important even in cells without transcriptional activities (e.g. platelets) (ref.28).

Supplementation with n-3 PUFA favourably influences acylation of proteins and functions of ion-channels in the myocardium improving electrical stability. It reduces the risk of sudden cardiac death as well as fatal myocardial infarction (DART Study, Lyon Heart Study and GISSI Prevenzione Trial) (ref.29,30).

Fatty acid role in signal transduction and gene transcription pathways

a. Modulators of gene transcription

Cell signalling ensures transfer of information between cells and disorder of cell signalling may be involved in disease pathogenesis. Signal pathways can be influenced by genes, nuclear factors and receptors. Fatty acids as ligands of these receptors or as modulators of gene transcription can significantly influence cell signalling. Long chain unsaturated FA (C20-22) and their metabolites have been identified as effective ligands of nuclear receptors of some transcription factors:

1) Peroxisome proliferator-activated receptor (PPAR) -α, -β/δ, -γ1 and -γ2
2) Liver X receptors (LXR) type α and β
3) Hepatic nuclear factor (HNF) 4α
4) Sterol regulatory element binding protein (SREBP) -1 and -2.
5) Carbohydrate regulatory element binding protein/Max-like factor X (ChREBP/MLX) (ref.31,32).

Dietary fat regulates the above transcription factors associated with hepatic glycolysis, fatty acid synthesis and oxidation. These transcription factors have various roles: SREBP-1 upregulates the activity of enzymes involved in FA synthesis (including PUFA), desaturation and elongation; ChREBP/MLX upregulates de-novo lipogenesis and MFA synthesis (but not PUFA synthesis), and induces glucose transporter-2 and L-pyruvate kinase involved in
glucose metabolism; PPAR-α induces mainly PUFA synthesis and FA oxidation; LXR induces de-novo lipogenesis and MFA synthesis33,34.

Long chain n-3 PUFA promote (as ligands) PPAR and inhibit LXR. The mechanism of PPAR action is shown in (Fig. 2). As shown, PPAR can be activated by FA (LC n-3 PUFA), eicosanoids and different drugs (fibrates, thiazolidinediones). They act through dimerisation with retinoid-X-receptor (RXR) in the nucleus35. The transcription factors interact with peroxisome proliferator-response elements (PPRE) in DNA encoding proteins involved in many important metabolic pathways (lipid and glucose homeostasis, hepatocarcinogenesis, adipose tissue homeostasis etc.) (ref.36).

Feedback regulation of HNF-4α is performed by thioesters of acyl-coenzyme A of PUFA. Furthermore, SREBP, which are sensors of intracellular lipid conversion, are engaged in the synthesis of cholesterol (SREBP-1 and -2), FA and TAG (SREBP-1c). Polyunsaturated FA, as well as some conjugated linoleic acid (CLA) isomers, modulate the content of liver mRNA encoding SREBP-1c or directly transcription of SREBP-1c. It has been shown that PUFA inhibit expression of SREBP. No corresponding effect of PUFA on adipose tissue has been found. Both n-3 and n-6 PUFA suppress ChREBP/MLX and interfere with glucose-regulated hepatic metabolism. As a result of the above effects of PUFA on transcription factors, PUFA promote FA oxidation and prevent FA synthesis and storage33,34.

b. Receptor interactions and signal transduction

Amide derivatives of FA were intensively studied in the fifties. N-palmitoylethanolamine from soya and egg yolk has been shown to have antiinflammatory action. Ethanolamine, ammonia and some bioactive amines are donors of the amino group in the reaction with FA. The resulting amides interact with cannabinoid as well as vaniloid receptors. Brain cannabinoid receptors take part in signal pathways of memory, movement, emotional and nociceptive processes. On the other hand, peripheral cannabinoid receptors play a role in the modulation of immunocompetent cells37.

Ethyl esters of FA, products of the non-oxidative metabolism of ethanol, are produced by a specific synthase. This results from chronic ethanol use. These esters can be ligands of PPAR, and other transcription factors, such as NFκB and activator protein 1 (AP-1) (ref.38). Nuclear factor κB exists in the cytosol of inflammatory cells in an
activation pathway, thus, reducing inflammation. Evidence suggests that LC n-3 PUFA may act as inhibitors of the NFκB elements affecting gene transcription. The receptor of platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycerol-3-phosphocholine) recognises PAF, which contains an ether bond in the sn-1 position of glycerophosphocholine and a residue of short FA in the sn-2 position, with high specificity.

Enterodocrine L cells are found throughout the gastrointestinal tract epithelium among enterocytes. L cells are activated by food components and their metabolites in the lumen, resulting in secretion of gut hormones. Specifically, 7TM G protein-coupled receptors, mostly found on the apical pole of L cells, function as chemosensors. Amongst other receptors, L cells have chemosensors for LCFA (GPR40, GPR120) and SCFA (GPR41, GPR434), the latter being degradation products (propionic, acetic, butyric acids) of complex polysaccharides by gut microbiota. Samuel et al. showed that the GPR41 receptor on L cells is essential for SCFA to act as a fuel and as signalling molecules. Reimann et al. managed to genetically tag L cells and culture them, in order to investigate secretion of glucagon-like peptide-1 (GLP-1) from L cells. This is an enteric hormone that stimulates insulin secretion and improves glycemia in Type 2 Diabetes. L cell chemosensor receptors are interesting drug targets to tackle metabolic disorders, diabetes, obesity and even cancer cachexia. Current studies focus on novel treatments including GLP-1, GLP-2, peptide YY (PYY), and ghrelin mimetics. A potential drug target could be the above mentioned LCFA and SCFA chemosensor receptors.

**Interactions between fatty acids and non-receptor proteins**

Some FAs (oleic, palmitoleic, arachidonic) are potent uncoupling agents of cell communication at the level of gap junctions (cell connecting proteins). The mechanism of action lies in the interaction between lipids and cell connecting proteins, specifically in myocytes.

Ion channels can be affected by FAs. Calcium channels of ventricular myocytes are directly activated by LC PUFA. The effect of DHA on the creation of slow potassium rectifying current is caused by its effect on the hminK subunit of calcium channels. Sodium channel isomers in the heart and muscle tissue are inhibited by different types of FA. The antiarrhythmic effects of LC n-3 PUFA are probably associated with these interactions.

**Fatty Acids in Health and Disease**

**Nutrition recommendations**

Nutritional recommendations regarding fat intake have been formulated by various bodies in Europe and worldwide, including: the German-Austrian-Swiss body, the Nordic Nutrition, the UK Committee on Medical Aspects of Food policy, the Nutritional Recommendations for the French Population, the Health Council of the Netherlands, the Dietary Guidelines for Americans, and the World Health Organisation. Recently, the European Food Safety Authority (EFSA) Panel on Dietetic Products, Nutrition, and Allergies (NDA) has reviewed these recommendations and scientific evidence available, and published a scientific treatise on Dietary Reference Values (DRV) for fats.

Dietary fat is one of the main energy substrates. It is recommended that total fat should be between a minimum of 20% and a maximum of 35% of TEI through food consumed by healthy adults. Fat intake for infants should be 40% of TEI between 6-12 months of age, and reduced to 35-40% of TEI for children aged 2-3 years old. It was proposed by EFSA that SFA and trans FA intake should be as low as possible (without setting a DRV), and that no DRV can be formulated for cis-monounsaturated FA (MFA) or cis-PUFAs. However, other bodies have set more specific targets for these types of fat. The above mentioned European and worldwide bodies recommend intake of 10-15% of TEI for cis FA, <10% of TEI for SFA, and <1-2% of TEI for trans FA. Also, adult intake of cis-MFA is recommended to be 10-15% of TEI by the Nordic Nutrition Organisation, whereas in France the recommendation reaches 20% of TEI. For cis-PUFA it has been recommended that intake should be between 5-10% of TEI. These recommendations are modified for impaired conditions where fat intake (mainly that of SFA) should be lower, such as in coronary heart disease (CHD), hypertriglyceridemia, diabetes, and the metabolic syndrome. According to the Therapeutic Lifestyle Changes (TLC) in LDL-lowering therapy of the Adult Treatment Panel III, a CHD and CHD risk equivalents, it has been recommended that SFA intake should be <7% of TEI, PUFA up to 10% and MFA up to 20% of TEI. Also, dietary cholesterol intake should be limited to <200 mg/day.

As far as EFAs are concerned, EFSA suggested an Adequate Intake (AI) of 4% of TEI for LA and 0.5% of TEI for ALA. Both, EFSA and the WHO have agreed that there is insufficient scientific evidence to support a recommendation for the n-3 to n-6 PUFA ratio; thus no DRV was set. Specific recommendations were given for LC n-3 PUFA. Increased dietary intake of preformed DHA is imperative for adequate DHA status in adults and infants, which cannot be achieved by DHA precursor supplementation (ALA, EPA) (ref.2). EFSA and the WHO set an AI of 250 mg for EPA plus DHA for adults. Specifically for infants and young children (<24 months) it was recommended that DHA AI should be 100 mg. During pregnancy and lactation it was recommended that additionally to the AI for LC n-3 PUFA, intake of DHA should be increased by 100-200 mg. Also, other bodies have recommended that DHA intake should be at least 200 mg/day in women of reproductive age, that pregnant women need to consume a minimum of 300 mg DHA/day, and that lactating women should aim to achieve an average dietary intake of at least 200 mg DHA/
Fatty acids as biocompounds: their role in human metabolism, health and disease – a review.
Part 2: fatty acid physiological roles and applications in human health and disease

Fatty acids in maternal and offspring health

Gestation, as well as the first months of life, are critical periods of organ development for the fetus and the newborn. Environmental exposures of the mother during gestation may predispose the fetus to modulating factors affecting health outcomes. Moreover, exposure to pollutants, intake of folic acid, vitamin D, antioxidants such as selenium, and most importantly LC n-3 PUFA may have cardioprotective effects and may be used for secondary prevention of CHD. Further randomised clinical trials and research would help to clarify the upper level of intake of LC n-3 PUFA (ref. 58, 59).

**Fatty acids in maternal and offspring health**

Gestation, as well as the first months of life, are critical periods of organ development for the fetus and the newborn. Environmental exposures of the mother during gestation may predispose the fetus to modulating factors affecting health outcomes. Moreover, exposure to pollutants, intake of folic acid, vitamin D, antioxidants such as selenium, and most importantly LC n-3 PUFA may have cardioprotective effects and may be used for secondary prevention of CHD. Further randomised clinical trials and research would help to clarify the upper level of intake of LC n-3 PUFA (ref. 58, 59).

**a. Fatty acids during gestation: maternal and placental metabolism**

During pregnancy there are two principal metabolic stages. During the first two trimesters fetal growth is limited and the mother accumulates nutrients and energy in her body stores. The last trimester is characterised by a catabolic phase whereby maternal adipose tissue lipolysis releases FA to the maternal circulation which will be transferred to the fetus through the placenta. Maternal non-esterified FA (NEFA) released from lipolysis are mainly re-esterified into TAG in the liver, and these are released into the circulation in the form of VLDL. There is an increase in plasma TAG concentration during late gestation and this is termed the hypertriacylglycerolemia of pregnancy. Also, during late pregnancy levels of TAG increase in LDL and HDL probably associated with increased activity of the cholesteryl ester transfer protein (CETP) (ref. 69). This enzyme controls TAG and CE exchange between VLDL, LDL, and HDL. Maternal hypertriacylglycerolemia is considered to be beneficial for the fetus, as it may enhance the availability of important FA from the mother. During late pregnancy, intestinal absorption of TAG is very efficient and TAG are carried in the form of chylomicrons in maternal plasma.

The function of the placenta and many physiological and metabolic adaptations taking place during pregnancy play a fundamental role in optimising the transport of FA to the fetus. Complex mechanisms are involved in placental fatty acid transport. Lipoproteins can be taken up by the placenta by lipoprotein receptors existing in the placenta. Also, because of the expression of lipoprotein lipases (LPL) on placenta, maternal TAG can be hydrolysed and the NEFA released can by taken up by the placenta. These can be re-esterified and stored, and then hydrolysed and released into the fetal bloodstream.

Transport of LC PUFA to the placenta is mainly done by uptake of maternal TAG intact in plasma. This is suggested to be greater than uptake of NEFA from the placenta. However, maternal plasma NEFA bound to albumin are also a source of LC PUFA for the fetus. Thus, FA to be transported by the placenta are derived mainly from TAG in chylomicrons or VLDL, from which they are released by TAG hydrolase/LPL before entering the placenta. The placenta uptake of circulating TAG is concentration gradient dependent.

Placenta FA composition can be indicative of maternal fatty acid status and reflects FA which are selectively transferred to the fetus. The placenta is mainly composed of phospholipids which comprise about 88% of total lipids. The placenta is dominated by PUFAs, followed by SFA (mainly palmitic and stearic acids), and MFA (mainly oleic) in lower percentages. Arachidonic acid is the major PUFA in placenta tissue. Its levels (about 22-25%) are higher than that of DHA and EPA, as well as LA and dihomo-gamma-linolenic acid (DGLA). Also, LA and DGLA (n-6 PUFA) are found in higher levels compared to placental LC n-3 PUFA (ref. 72, 74, 75). In relation to this, AA-derived PG are related to the maintenance of pregnancy and initiation of labor.

The presence of membrane FA binding protein in human placenta results in preferential transfer of certain FAs to the fetus. It has been well demonstrated that maternal and cord plasma at delivery have a different fatty acid profile in almost all lipid fractions (including CE and PC), with umbilical cord plasma exhibiting a higher concentrations of AA and DHA. This indicates selective mobilisation of LC PUFAs from the placenta and their preferential supply to the fetus. Also, it has been shown that pregnancy is associated with a decline in percentage levels of AA and DHA in maternal plasma TAG, which may indicate the selective transfer of these FAs to the fetus. Preferential transfer of LC PUFA (mainly DHA) is higher than EPA transfer. The fetus depends on placental LC PUFA supply because fetal Δ6- and Δ5-desaturase activity is very low in utero, and the placenta...
lacks enzymatic activity for the conversion of EFA to LC PUFA (ref.71,74).

Various studies have shown that maternal plasma and red blood cell FA percentages were highly significantly correlated with fetal and neonatal FA (ref.80,81). Also, it has been demonstrated that maternal LC n-3 PUFA dietary intake during pregnancy was positively associated with maternal blood levels and significantly correlated with cord blood levels of these FA (ref.72,83). Consequently, maternal dietary intake of LC PUFA is related to the availability of these FAs to the fetus71.

During pregnancy a woman must meet the additional demands related to the accretion of maternal, placental, and fetal tissues. Although, the formation of DHA and EPA appears to be tightly regulated, a marginal state for many women during pregnancy and lactation cannot be excluded56. Also, maternal LC n-3 PUFA status decreases with the number of consecutive pregnancies64,85. Therefore, it is imperative for women of reproductive age to sustain a good LC n-3 PUFA status in order to support fetal demands of present and future pregnancies.

Excess intake of total fat during pregnancy, mainly trans and saturated fat, can lead to gestational hyperglycemia and gestational diabetes mellitus, whereas PUFA intake is linked with a lower risk56. Similarly, increased intake of LC n-3 PUFA may be protective against preclampsia7.

b. Fatty acids in utero: fetal growth and development

Fatty acids are required by the developing fetus in order to maintain fluidity and structure of membranes, as well as to act as precursors of eicosanoids71. Long-chain PUFA (mainly DHA and AA) are important for fetal growth and development72,74 and they influence length of gestation69,74. It was shown that maternal DHA status in early gestation was positively associated with birth weight and head circumference69. Lengthening of gestation results in lower risk of preterm birth is beneficial for both the mother and the fetus. Systematic reviews and meta-analyses have concluded that: maternal LC PUFA supplementation reduced preterm delivery96, marine oil supplementation mildly increased the length of gestation97, fish oil supplementation during pregnancy decreased the risk of preeclampsia, preterm birth, low birth weight and small-for-gestational age8. The effect of fish oil supplementation on gestational length seems to be more evident in women with a low or moderate habitual intake of fish8.

Docosahexaenoic acid is accumulated in high concentrations in the membranes of cells of the fetal nervous and visual systems (i.e. in fetal brain and retina) during pregnancy99, and this accumulation is very important for visual and cognitive development both before and after birth100. High amounts of DHA are incorporated into membranes in the brain and retina especially during the last trimester of pregnancy, when fetal nervous system growth is very rapid74. Total fetal DHA accretion in utero takes place mainly in the last 10 weeks of pregnancy71. Most of the DHA is stored in fetal adipose tissue in utero (50 times more than in fetal brain) in order to be released after birth and utilised for growth. Accretion of LC PUFA in utero results in higher concentration of DHA and AA in the fetal adipose tissue compared to maternal71. In general, LC PUFA levels increase from maternal tissues to fetal circulation to fetal tissues (known as biomagnification) (ref.101).

It is known that preterm birth, which curtails maternal supply of DHA to the fetus, is associated with sub-optimal neural and visual development, which can be improved by providing exogenous DHA (ref.53,102). Several maternal fish oil supplementation studies during the second half of gestation have shown that maternal and cord blood EPA and DHA status are improved following supplementation93,104. Maternal supplementation with LC n-3 PUFA during pregnancy59,103,106. or lactation107,108, or both109,112 have been shown to result in improved cognitive and/or visual function. These studies have been recently reviewed by Brenna & Lapillonne (2009) (ref.113).

Long chain n-3 PUFA have also been shown to influence immune function7. A point to be considered is the origin of n-3 PUFA. It was recently shown in a rat study, that fish oil, but not linseed oil, intake during pregnancy reduced antibody response in the offspring and potentially increased T-helper type 1 (Th1) polarisation114. It has been shown that LC n-3 PUFA status in maternal blood and umbilical cord blood is lower in mothers of allergic (atopic) children115,116. It is now considered that supply of EPA and DHA to the fetus might be important in promoting appropriate immune development117,118. With regard to the latter, there is some evidence that early fish and LC n-3 PUFA exposure protects against immune dysfunctions like sensitisation to allergens (atopy), allergy and asthma in infancy and childhood119. Epidemiological studies looking at the effect of maternal fish consumption during pregnancy and fish consumption during infancy/childhood suggest that fish consumption may play a protective role against atopic disease development in children. It has been shown that fish oil supplementation during pregnancy and lactation resulted in higher LC n-3 PUFA provision and status in the offspring93,100,102,123. Early fish oil provision was associated with immunologic changes in cord blood which may be consistent with decreased risk of atopy in the offspring and such changes may persist118. These studies suggested clinical benefits of early fish oil provision including reduced sensitization to common food allergens and reduced prevalence and severity of atopic dermatitis in the first year of life, again with a possible persistence until adolescence with a reduction in eczema, hay fever, and asthma. Also, studies of fish oil supplementation during infancy or childhood have shown protective effects, although the evidence is heterogeneous119.

c. Fatty acids postnatally: breast milk and infant development

Maternal breast milk is of great importance in humans and other mammals since it is the main source of all nutrients for the newborn. Early exposure of the newborn to specific factors through breast milk including FA, immunoglobulins, minerals, vitamins, but also possible environmental pollutants including maternal smoking124,125,
is fundamental in modulation and programming of health and disease outcomes later on in life.

Breast milk fatty acid composition is very much dependent on maternal dietary fat intake during gestation which is deposited in adipose tissue and released into breast milk during lactation. Thus, the type of dietary fat consumed during pregnancy will determine not only the fatty acid profile of the mother and the fetus, but also that of breast milk to be provided to the newborn. In relation to this, maternal fish oil supplementation during gestation significantly increased breast milk content in LC n-3 PUFA (ref.128,129). However, there are also LC n-3 PUFA supplementation studies during lactation showing increased breast milk EPA and DHA content after supplementation130,131. Moreover, dietary trans FA intake during pregnancy and lactation are directly related to breast milk concentration of trans FA (ref.132).

Preformed LC n-3 PUFA, particularly EPA and DHA, need to be provided to infants to meet the high requirements of rapidly growing tissues and organs. The human brain growth spurt initiates at week 28 gestation and continues during the first year of life131,132, while AA and DHA are important also during the second year133. Obviously, the brain is the most critically developing tissue in the human. It is composed of specific lipids like sphingosine-derived lipids and other phospholipids. About 50% of FA in brain lipids are n-3 PUFA, like EPA and DHA. Phosphatidylcholine (lecithin) is one of the most important phospholipids in brain tissue (approx. 10% of dry weight). Although, LC n-3 PUFA are released from the neonate’s adipose tissue, their exogenous source is breast milk which in humans is rich in these FA and PC during the first weeks of lactation. Breast milk fat content is about 3-4% by weight and fat provides about 50-60% of total energy. Human milk provides mainly SFA (palmitic) and MFA (oleic) (ref.134). Typically, DHA (0.2-1.1%) and AA (0.3-0.7%) are the dominant LC PUFA in breast milk, with DHA being more variable and sensitive to maternal dietary intake135,136. Sphingomyelin is one of the quantitatively most important components of breast milk; its level seems to be rather constant for at least 3 months. Breast milk contains more sphingomyelin than cow’s milk, which is also an important source of this compound. Also, human and cow’s milk contain PUFA and choline. Thus, breast milk is a great source of the fundamental lipids for brain development. In the case of neonates that are not being breastfed, fish oil supplemented infant milk formulas are used137,138. The adult brain needs constantly the provision of the same nutrients (sphingomyelin) as that of a developing child. Cow’s milk is probably a valuable source of these compounds. Therefore, dairy products are important components of the human diet. However, as a significant number of adults do not consume enough dairy products, these important nutrients should be obtained from other foods, such as oily fish which are rich sources of LC n-3 PUFA.

Breast milk FA content is also important for other aspects of neural development, such as cognition and vision, as well as immune development of the infant. There is some evidence from observational140,142 and fish oil supplementation studies143,144,145 showing a significant positive correlation between visual acuity and cognitive function later on in infancy and childhood and DHA levels in breast milk or infant DHA status. Also, there is evidence that LC n-3 PUFA status in breast milk is lower in mothers of allergic (atopic) children146,147. Thus, increased intake of LC n-3 PUFA through breast milk may be protective against allergic disease development148,149. On the other hand, it was recently shown that increased maternal intake of butter and SFA during lactation was associated with increased risk of allergic sensitisation in the offspring at age 5 years150. Lastly, increased provision of LC n-3 PUFA later on in infancy and early childhood (through increased oily fish consumption or LC PUFA supplementation) has also been shown to decrease the risk of allergic disease development149,152 and has been associated with better visual acuity153,154 and cognitive function155,156, although these effects need to be further investigated. The effects of PUFA on child attention deficit and hyperactivity disorders are not yet clear as the existing evidence is inconclusive157.

Genetic polymorphisms in FA desaturase genes modify the association between FA intake and maternal and breast milk FA status. Also, genetic variability in pregnant women may affect FA provision to the fetus and thus its growth and development. The beneficial effects of breast feeding can be altered by the mother-infant-pair genotype. Gene-diet interactions should be taken into account when investigating the effects of maternal diet on the offspring health.

**Fatty acid pathophysiology and gene interactions**

Fatty acid composition is primarily determined genetically and it is tissue and species specific. Dietary fat influences fatty acid status and is reflected in fatty acid composition of plasma and adipose tissue158,159. A number of pathological stages may accompany changes in fatty acid composition due to increased intake of animal fat and decreased intake of vegetable and marine origin oils160,161. This is often expressed as decreased content of PUFAs (mainly n-3 PUFA) and increased content of SFA in states such as dyslipidemia, malnutrition, inflammation, oxidative stress, inherited diseases, and other common metabolic abnormalities (metabolic syndrome, Type 2 diabetes).

The variation in desaturase genes, as part of complex gene-lifestyle interactions, has an important role in determining plasma lipid profiles. This introduces a nutrigenomics approach to disease control and prevention162. Polymorphisms in the genes encoding Δ5- and Δ6-desaturases, FADS1 and FADS2 respectively (chromosome 11q12-11q13.1), have been associated with PUFA and LC PUFA status and cholesterol levels. A case-control study in Korea showed that the T allele of the single nucleotide polymorphism (SNP) rs174537 (flapstructure specific endonuclease; FEN1) near FADS1 was associated with lower risk of coronary artery disease. Also, T allele FEN1 carriers had significantly higher levels of LA and lower levels of AA compared to G/G subjects. This was also associated with reduced total and LDL-cholesterol and...
Table 2. Factors influencing the activity of desaturases and elongases.

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Activation</th>
<th>Inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Nutrition factors</td>
<td></td>
</tr>
<tr>
<td>Δ6-desaturase</td>
<td>ATP deficiency of EFA</td>
<td>ethylalcohol fasting</td>
</tr>
<tr>
<td></td>
<td>deficiency of Phe, Tyr</td>
<td>glucose, glycerol deficiency of proteins</td>
</tr>
<tr>
<td></td>
<td>high-protein diet</td>
<td>deficiency of pyridoxine</td>
</tr>
<tr>
<td></td>
<td>fat-free diet</td>
<td>exogenous cholesterol</td>
</tr>
<tr>
<td></td>
<td>Zn, Mg</td>
<td>n-3 and n-6 PUFA</td>
</tr>
<tr>
<td></td>
<td>pyridoxine</td>
<td>SFAs</td>
</tr>
<tr>
<td></td>
<td>ethylalcohol fasting</td>
<td>excess intake of Phe and Tyr trans-MFA</td>
</tr>
<tr>
<td>Δ5-desaturase</td>
<td>insulin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LA, GLA, AA</td>
<td>glucagon (cAMP)</td>
</tr>
<tr>
<td></td>
<td>columbinic acid</td>
<td>adrenalin (cAMP)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>glucocorticoids</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ADH, ACTH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>hyper-, hypo-T&lt;sub&gt;3&lt;/sub&gt;, T&lt;sub&gt;4&lt;/sub&gt;</td>
</tr>
<tr>
<td>Elongase</td>
<td>glucose supply</td>
<td></td>
</tr>
<tr>
<td></td>
<td>deficiency of EFA</td>
<td>fat-free diet</td>
</tr>
<tr>
<td></td>
<td>fasting</td>
<td>exogenous cholesterol</td>
</tr>
<tr>
<td></td>
<td>fat-free diet</td>
<td>trans-MFA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>deficiency of proteins</td>
</tr>
<tr>
<td></td>
<td></td>
<td>glucose</td>
</tr>
<tr>
<td></td>
<td></td>
<td>vitamin A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PUFA n-3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>glucagon, adrenalin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>glucocorticoids</td>
</tr>
</tbody>
</table>

120:5 n-3, 22:5 n-3, 22:6 n-3, 18:3 n-6, 20:3 n-6  

AA, Arachidonic acid; ACTH, Adrenocorticotropic hormone; ADH, Antidiuretic hormone; AMP, Adenosine monophosphate; ATP, Adenosine triphosphate; EFA, Essential fatty acid; GLA, γ-Linolenic acid; LA, Linoleic acid; MFA, Monounsaturated fatty acid; Phe, Phenylalanine; PUFA, Polyunsaturated fatty acid; SFA, Saturated fatty acid; T<sub>3</sub>, Triiodothyronine; T<sub>4</sub>, Thyroxine; Tyr, Tyrosine.

In the Doetinchem Cohort Study, it was concluded that dietary intakes of n-3 and n-6 PUFA interact with FADS1 polymorphism to affect plasma total and HDL-cholesterol levels. In populations consuming a Western diet, it has been shown that the FADS polymorphism which is associated with higher desaturase activity may result in higher risk of proinflammatory response, and thus, atherosclerosis. Also, carriers of the rare allele of FADS SNP and their haplotypes had altered eicosanoid precursor levels and a lower prevalence of allergic disease and topical eczema. Interactions have also been shown between the APOA1 and FEN1 polymorphisms and AA and n-6 PUFA levels in serum phospholipids and coronary artery disease. Further, polymorphisms at the 5-LOX and COX-2 level have been shown to increase the risk of CHD and prostate cancer respectively, depending on DHA, EPA, LA and ALA intake. Thus, studies investigating the association between genetic variation and disease should include diet (and FA intake) in their analysis. As blood levels of PUFA are not only diet-dependent, but also influenced by genetic variants, it has been suggested that...
dietary requirements of PUFA should take into account these genetic polymorphisms. Also, FADS polymorphism analyses should be included in studies focusing on the biological effects of PUFAs (ref.172).

It is interesting that metabolic disorders of different manifestation, such as extreme leanness in anorexia nervosa and obesity in the metabolic syndrome, result in similar changes in FA lipid profile. A characteristic marker in both disorders is the increased content of palmitoleic acid (also a marker of lipogenesis). This results from increased activity of Δ9-desaturase which converts palmitic to palmitoleic acid. A second marker is the decreased content of LA which probably results from several factors (decreased food intake, increased peroxidation and β-oxidation, increased conversion of AA to eicosanoids) (ref.173,174). Anorexia nervosa, a condition of extreme starvation, has been characterised by changes in plasma lipids and lipoproteins. Specifically, it was shown that patients with anorexia nervosa had raised total cholesterol, TAG, HDL-cholesterol, campesterol, and β-sitosterol. Also, there was a decrease in n-6 PUFA and LA, and an increase in palmitoleic acid in all plasma lipid classes173. The common SNP (C to T substitution) in the first intron of the FA coenzyme A ligase-4 (FACL4) gene has been investigated in relation to FA metabolism in the metabolic syndrome and in depression. In metabolic syndrome patients, T allele carriers were characterised by higher content of DGLA and lower content of AA in plasma PC, lower index of Δ5 desaturation and unsaturation index. The studied SNP was not associated with markers of FA metabolism in depressed patients175.

Essential fatty acid deficiency

Fatty acid status depends (apart from other factors such as genetics and the diet) on the activity of desaturation and elongation enzymes of their metabolic cascade178. Factors influencing the activity of these enzymes are summarised in (Table 2).

Deficiency of EFA leads to a number of disorders, which are summarised in (Table 3). Essential FA deficiency has been known since the 30’s of the last century177. In animal experiments, EFA deficiency was linked to growth retardation and increased transepidermal losses of water as a result of increased skin permeability. In both males and females, EFA deficiency causes infertility and it results in a lower AA content which is an eicosanoid precursor178,180. Also, there is an increased desaturation and elongation of oleic acid to Mead acid (20:3n-9) in order to preserve membrane fluidity and produce alternative precursors for eicosanoid synthesis181,182. Increased fragility of capillaries and haematuria is linked to disrupted biomembrane stability. Experiments showed increased food consumption in animals with negative nitrogen balance and lowered production of ATP in parenchymal organs (liver, myocardium); this effect is related to decreased contractility of the myocardium and abnormal QRS in electrocardiogram. Essential FA deficit in the liver leads to lower cholesterol transport, probably connected to secondary dyslipidemia and slower reverse cholesterol transport. Clinical markers include abnormal adaptation to darkness (dysopsia) and lower visual acuity, as well as motor neuropathies183,184. In the 90’s, the pathophysiological and clinical differences between n-3 and n-6 PUFA deficiencies were defined as shown in (Table 4).

Oxidative stress

Dietary supplementation with n-3 PUFA had been related to enhanced oxidative stress and increased oxidative modification of LDL in comparison to n-6 PUFA supplementation. However, new findings suggest that incorporation of PUFA into phospholipids leads to conformational changes and lowered availability of double bonds for lipoperoxidation. Also, the peroxyl radicals derived from

<table>
<thead>
<tr>
<th>Growth disturbances</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased transepidermal losses of water (increased skin permeability)</td>
</tr>
<tr>
<td>Increased predisposition to bacterial infections</td>
</tr>
<tr>
<td>Male and female infertility</td>
</tr>
<tr>
<td>Decreased status of AA/ increased status of Mead acid (20:3n-9)</td>
</tr>
<tr>
<td>Disturbed stability of biomembranes</td>
</tr>
<tr>
<td>Disturbed cholesterol transport</td>
</tr>
<tr>
<td>Increased fragility of capillaries</td>
</tr>
<tr>
<td>Kidney failure (haematuria, hypertension)</td>
</tr>
<tr>
<td>Lower contractility of myocardium</td>
</tr>
<tr>
<td>Abnormal QRS in electrocardiogram</td>
</tr>
<tr>
<td>Lowered production of ATP (myocardium, liver)</td>
</tr>
<tr>
<td>Dysopsia (lowered visual acuity, disturbed adaptation to darkness)</td>
</tr>
<tr>
<td>Neurological disturbances (sensor and motor neuropathies)</td>
</tr>
<tr>
<td>Increased food demand with negative nitrogen balance</td>
</tr>
<tr>
<td>Disturbed synthesis of eicosanoids</td>
</tr>
</tbody>
</table>

Table 3. Essential fatty acid deficiency syndrome.

AA, Arachidonic acid; ATP, Adenosine triphosphate
EPA are more hydrophilic than those generated from LA. They diffuse more readily through lipoprotein envelopes and radical reaction can be terminated more rapidly on the lipoprotein surface\(^{186,187}\).

Increased dietary intake of n-3 versus n-6 PUFA results in enhanced transcription of antioxidant enzymes (uncoupling protein 2, glutathione transferase 2τ, superoxide dismutase) and in suppressed transcription of enzymes taking part in the production of reactive oxygen and nitrogen species (RONS). Intake of n-6 PUFA increased activities of glutathione peroxidase, superoxide dismutase and catalase\(^{187,188}\). Increased severity of the metabolic syndrome has been associated with increased oxidative stress and unfavourable fatty acid metabolism. Increased severity of the metabolic syndrome was also linked to increased content of SFA and activities of Δ9- and Δ6-desaturases, decreased content of n-6 PUFA and Δ5-desaturase activity\(^{189}\). Also, in men with the metabolic syndrome, the presence of the T allele of the microsomal TAG transfer protein (MTP)\(^{-493}G/T\) polymorphism was associated with increased NEFA, plasma total cholesterol, plasma TAG, and VLDL. Carriers of the T allele had lower concentrations of plasma n-6 PUFA in phospholipids, lower Δ5-desaturase activity and higher concentrations of conjugated dienes in LDL. These effects were not observed in healthy men or in women (with or without metabolic syndrome) (ref.\(^{174}\)).

**Cardiovascular health and blood lipids**

Excess intake of fat predisposes to higher risk of impaired postprandial lipemia which triggers a proinflammatory state and results in increased risk of cardiovascular disease (CVD) (ref.\(^{190,191}\)). However, different effects are caused by different types of fat consumed\(^{192,193}\) also depending on genetic polymorphisms. Carriers of *FADS1* and *FADS2* haplotypes which are associated with higher desaturase activity had higher risk for coronary artery disease and inflammation\(^{167}\). Increased SFA intake is linked to increased plasma LDL-cholesterol levels and increased risk of CVD\(^{190}\), although stearic acid seems to have milder effects\(^{193-195}\). Also, the effect of increased trans FA intake has been well documented to be negative since it promotes CVD development\(^{196,197}\). Milk contains also trans FA (predominately trans vaccenic and rumenic acids) but probably humans have adapted to these levels (see part 1 of this review). When plant oils are hydrogenated different trans FA are formed. Elaidic acid is a characteristic trans FA which is generated by low quality catalysis during margarine production. Technologies have been developed to minimise trans FA production in industrial and cooking processes\(^{198}\), although they still appear in food consumed. Further advances in these technologies are required.

In contrast, high MFA intake from olive oil has been shown to be cardioprotective, resulting in increased HDL-cholesterol and decreased LDL-cholesterol. Also, the Mediterranean dietary pattern which is characterised by high consumption of olive oil has been related to lower risk of cardiovascular disease mortality\(^{199}\). As far as PUFAs are concerned, various studies have shown that their effect is beneficial compared to SFA (ref.\(^{190}\)). However, differential effects are caused by n-6 and n-3 PUFA (ref.\(^{161}\)), with a greater cardioprotective effect shown for n-3 PUFA (ref.\(^{200}\)). In a recent meta-analysis it was shown that increasing intake of n-6 PUFA alone increases the risk of myocardial infarction and CHD death compared to simultaneously increasing n-6 and n-3 PUFA (ref.\(^{201}\)).

Increased intake of n-6 PUFA probably results in increasing risk of coronary artery disease in populations where this increased risk cannot be explained by conventional risk factors\(^{202}\). A randomised single-blind trial in patients with high risk of coronary artery disease, investigated the cardioprotective effects of an Indo-Mediterranean diet rich in ALA (grains, fruit, walnuts, almonds, soybean oil) compared to the Step I National Education Program prudent diet (total fat <30% TEI, SFA<10% TEI, dietary cholesterol <300mg/day). It was shown that the Indo-Mediterranean diet protected from

<table>
<thead>
<tr>
<th>Deficiency</th>
<th>n-3 PUFA</th>
<th>n-6 PUFA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical symptoms</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>normal skin, growth and reproduction</td>
<td>growth retardation</td>
<td></td>
</tr>
<tr>
<td>normal skin, growth and reproduction</td>
<td>skin lesions</td>
<td></td>
</tr>
<tr>
<td>abnormal electroretinogram</td>
<td>disturbed reproduction</td>
<td></td>
</tr>
<tr>
<td>dysopsia</td>
<td>steatosis</td>
<td></td>
</tr>
<tr>
<td>polydipsia</td>
<td>polydipsia</td>
<td></td>
</tr>
<tr>
<td><strong>Biochemical parameters</strong></td>
<td>↓ 18:3n-3 and 22:6n-3</td>
<td>↓ 18:2n-6 and 20:4n-6</td>
</tr>
<tr>
<td>↑ 22:4n-6 and 22:5n-6</td>
<td>↑ 18:2n-6 and 20:4n-6</td>
<td></td>
</tr>
<tr>
<td>↑ 20:3n-9 (only with parallel ↓ of PUFA n-6)</td>
<td>↑ 20:3n-9 (only with parallel ↓ of PUFA n-3)</td>
<td></td>
</tr>
</tbody>
</table>

PUFA, Polyunsaturated fatty acid.
levels of AA (ref.22). This has been related to inhibition of
fatty acid status. It has been shown that supplemen-
tion of less inflammatory potent eicosanoids, resolvins,
and particularly rich in LC n-3 PUFA due to high intake
of WH and seal meat and fat204. It was then proposed
that a high intake of LC n-3 PUFA may be protective
against cardiovascular mortality related to modification
of blood lipid profile, platelet aggregation and blood clot-
ing. Various studies have shown that use of fish oil is ad-
vantageous for the prevention of CHD. This is attributed
mainly to the antiarrhythmic and antithrombotic effects
of LC n-3 PUFA (ref.208), combined with normalisation
of endothelial dysfunction and blood lipid profile. According
to the American Hearth Association, the recommended
daily dose of LC n-3 PUFA in secondary prevention
of CHD is 1 g EPA and DHA.

According to the findings of the GISSI Prevenzione
Trial29,205, supplementation for 3.5 years with LC n-3
PUFA (1g/day) versus placebo to patients surviving a
recent myocardial infarction, resulted in relative risk re-
duction for cardiovascular, coronary, and sudden death
(30-45%) (ref.209). It has also been shown that fish oil sup-
plementation in patients awaiting carotid endarterectomy
(1.4 g EPA plus DHA/day) resulted in increased LC n-3
PUFA incorporation in atherosclerotic plaques and it was
associated with a decreased number of macrophages and
increased plaque stability208. In relation to these findings,
consumption of fish and vegetable oils has been shown
to be protective, whereas consumption of full fat dairy
products and hydrogenated fat has been associated with
increased risk of coronary artery disease207. Also, habitual
high fish consumption in Japan has been associated with
lower risk of hypercholesterolemia and lower risk of CHD
(ref.209).

Apart from the antiarrhythmic and antithrombotic
effects of LC n-3 PUFA, their antiinflammatory effect is
very important since inflammation is a substantial com-
ponent of CVD (ref.21). Eicosanoid production is affected
by fatty acid status. It has been shown that supplementation
with LC n-3 PUFA results in higher levels of EPA
and DHA in plasma and mononuclear cells and lower
levels of AA (ref.212). This has been related to inhibition
of AA-derived lipid mediator production, and higher produc-
tion of less inflammatory potent eicosanoids, resolvins,
docosatrienes derived from EPA and DHA (ref.209). Also,
supplementation with fish oil has resulted in lower cy-
tokine production (IL-1, IL-6, TNF-α) and T-lymphocyte
proliferation212, predisposing to a less inflammatory envi-
ronment which may enhance the cardioprotective proper-
ties of LC n-3 PUFA (ref.211).

The TAG-lowering effect of LC n-3 PUFA has been
well demonstrated, however, the magnitude of the effect
varies depending on the dose of supplementation212,213. At
present, n-3 PUFA ethyl esters are registered for treatment
of dyslipidemia in several countries (e.g. USA, Austria).
It should be stressed that the dose of n-3 PUFA neces-
sary for the induction of gene expression is 3-5 times
higher than the dose for EFA deficiency prevention.
Polyunsaturated FAs are used also as combination therapy
with fibrates, statins or nicotinic acid, when monotherapy
is not successful. It has been shown that in patients with
severe hypertriglyceridemia, mainly Type V hyperlip-
oproteinemia (increased chylomicrons and VLDL), the
combination of bezafibrate and n-3 PUFA supplemen-
tation resulted in marked decrease of TAG. The effect
of fibrates and n-3 PUFA is additive in lowering TAG
concentrations214. In patients with diabetic dyslipidemia
treated with statin-fibrate combination, supplementation
with n-3 PUFA further decreased plasma TAG, total
homocysteine and microalbuminuria216. A randomised
double-blind trial in CHD patients receiving either stat-
ins or fibrates showed that lipid lowering drugs affect
EFA metabolism. In both treatment groups, AA levels
were increased and LA levels were decreased. Also, ALA
and DHA decreased only in the fibrate treatment group.
These results have raised questions over whether a diet
low in n-6 PUFA and high in n-3 PUFA may ameliorate
drug effectiveness216. A systematic review of randomised
controlled trials showed that among antilipidemic agents
and diet, statins and n-3 PUFA are the most protective
against overall and cardiac mortality. It was shown that
n-3 PUFA alone decreased total mortality by 23% and
cardiac mortality by 32% (ref.217).

Insulin sensitivity and the metabolic syndrome

Dietary fat affects insulin sensitivity and secretion218.
Inulin release from β-cells of Langerhan’s islets is up-
regulated during acute increased exposure to FA (specifi-
cally 18:0). However, the effect of FA on insulin release is
inhibitory during long-term increased levels of FA which
deteriorate insulin resistance. Also, the effect of FA on
insulin secretion is influenced by their chain length and
degree of unsaturation218. Insulin release is enhanced
more by SFA than PUFA. The mechanism of this β-cell
response is not known, although it has been suggested
that an unknown FA metabolite (receptor) resulting from
insulin action through SREBP-1c is involved220. A study
showed that postprandial β-cell function and insulin sen-
sitivity improved with increased proportion of MFA to
SFA in dietary fat221. Also, population studies have shown
a favourable relationship between MFA intake and β-cell
insulin secretion221.

Mice studies have shown that high fat diets promote
hyperglycemia, insulin resistance, and non-alcoholic fatty
liver disease. These effects are associated with suppressed
expression of enzymes involved in PUFA synthesis and
decreased LC n-3 PUFA content in the liver. Insulin pro-
motes gene expression of the glycolytic enzyme L-pyruvate
kinase, while n-3 PUFA suppress its expression23,24.

High intake of dietary fat in humans has been associ-
ated with increased risk of obesity, Type 2 diabetes and
the metabolic syndrome222. Even in developing countries
where nutrition transition takes place, there are indica-
tions that increased intake of SFA and n-6 PUFA, and
decreased intake of MFA and n-3 PUFA may contribute to the development of these diseases\(^1\).

In the treatment of the metabolic syndrome, LC n-3 PUFA, apart from having beneficial effects on the cardiovascular and hemodynamic components, they may also affect insulin sensitivity, however, the existing evidence is inconclusive\(^{224}\). A randomised cross-over dietary intervention in young iron-deficient women examined the consumption of either 4 portions of oily fish or red meat per week. It was shown that in the oily fish group insulin sensitivity was improved\(^{233}\). Fish oil supplementation studies in overweight and/or hypertensive individuals have also shown improvement of glucose-insulin metabolism\(^{216,227}\).

**Critically ill patients, cancer and other chronic diseases**

Increased fat consumption has been associated with the development of specific types of cancer such as breast, colonic and pancreatic cancer\(^{225}\). Although the amount of total fat is important, it has been shown that the type of fat also plays a significant role\(^{229}\). Saturated FA and MFA have been shown to have only a weak effect on promoting tumours. In contrast, n-6 PUFA have been associated with a greater capacity to induce tumour formation\(^{230}\). However, epidemiological studies show that SFA and animal fat increase the risk of colon and breast cancer\(^{231}\). Long chain n-3 PUFA have been shown to have inhibitory effects in tumour formation, probably through alteration of PG synthesis and inhibition of cell proliferation in colon and breast cancer\(^{230}\). As the Western diet contains disproportionately high amounts of n-6 PUFA and low amounts of n-3 PUFA, the resulting high n-6/n-3 PUFA ratio is thought to contribute to cancer\(^{232}\).

Population based studies have shown that high intake of fat, particularly that of SFA, has been associated with increased risk of pancreatic cancer\(^{233,235}\). Evidence shows that fish oil supplementation may prevent cachexia in pancreatic cancer patients\(^{236}\). Epidemiological data show that high intake of LC n-3 PUFA (\(>0.85\) g/day) is associated with lower risk of developing pancreatic cancer (odds ratio, 0.47) (ref.\(^{237}\)). It has been demonstrated that the effect of LC n-3 PUFA on pancreatic function may be mediated by inhibition of PG and pro-inflammatory cytokine synthesis\(^{238,239}\). Particularly, the anticarcinogenic properties of LC n-3 PUFA, which are mainly attributed to altered PG formation due to COX-2 inhibition, may prove beneficial in pancreatic cancer\(^{240}\). Fish oil in total parenteral nutrition improved patient recovery and indices of pancreatic and hepatic function in postoperative cancer patients\(^{230,241}\).

After elective surgery for cancer, enteral nutrition supplemented with LC n-3 PUFA resulted in reduction of gastrointestinal complications and infections by 50% (ref.\(^{242,243}\)). Enteral nutrition enriched with EPA in critically ill patients with Adult Respiratory Distress Syndrome (ARDS) has been associated with decreased infiltration of neutrophils in the lungs, improved respiration, and shorter hospitalisation in intensive care unit (ICU). Treatment with LC n-3 PUFA seems to be effective in preventing disseminated intravascular coagulation and ARDS. Lipid emulsions used in parenteral nutrition prevent low energy intake but also improve outcome by modulation of oxidative stress and inflammation. Recently developed lipid emulsions have substituted soybean oil with oils rich in medium chain triglycerides (MCT), n-9 MFA (ref.\(^{244}\)) and n-3 PUFA (ref.\(^{245,246}\)). A decreased state of PUFA in lipids of septic patients has been documented and this may be linked to increased severity of their critical condition\(^{247}\). A randomised controlled study of fish oil in parenteral nutrition of septic ICU patients showed that fish oil modified inflammatory cytokine production and was associated with shorter hospitalisation\(^{248}\).

Isolated ethyl esters of DHA may improve clinical and biochemical parameters in children with disorders of peroxisome biogenesis (Zellweger syndrome, neonatal adrenoleukodystrophy, infantile Refsum’s disease) (ref.\(^{249,250}\)). Enteral supplementation with lipid emulsion containing LC n-3 PUFA and MCT had beneficial effects in patients with chylomicronemic syndrome combined with severe acute pancreatitis.

Fatty acids are also important in protein-energy malnutrition. Losses of skeletal muscle in some types of protein-energy malnutrition are associated with enhanced protein catabolism due to the effect of TNF-α, glucocorticoids and proteolysis inducing factor (PIF) on skeletal muscle proteins. Supplementation with EPA was shown to attenuate degradation of skeletal muscles probably by inhibition of PIF. In experimental models, EPA inhibited proteosome activity by reducing its expression\(^{250,251}\).

**Immune system disorders**

Fatty acids have been shown to affect inflammatory processes and, thus, diseases with an inflammatory component\(^{24}\). Chronic inflammatory conditions that are related to Th1 response dysregulation are characterised by inappropriate production of AA-derived eicosanoids (PGE2 and LTB4) and inflammatory cytokines. Since n-3 PUFA from fish oil act to decrease AA-derived eicosanoid production, it has been suggested that fish oil may have a preventive or therapeutic role for these diseases\(^{21}\). Supplementation trials have been conducted for most of these diseases. Clinical trials provide good evidence of the antiinflammatory and clinical improvement effects of fish oil on rheumatoid arthritis\(^{252,253}\) and inflammatory bowel diseases (Crohn’s disease and ulcerative colitis) (ref.\(^{255,256}\)). However, the therapeutic effect of fish oil on other conditions, such as multiple sclerosis and systemic lupus erythematosus, is not clearly evident\(^{257,258}\). Polymorphisms in the cluster of chromosome 11 that encodes Δ5- and Δ6-desaturases (11q12-11q13.1) have been associated with asthma, atopy, osteoarthritis, bipolar disorder, and Type 1 diabetes\(^{172}\).

Immune disorders characterised by polarisation towards T-helper type 2 (Th2) responses (mainly IL-5 and IL-4 secretion), such as atopy (allergies, eczema, asthma, hay-fever), may also be influenced by the type of dietary fat ingested. The hypothesis that has evolved is that an increased intake of n-6 PUFA accompanied by a low intake of n-3 PUFA has played a causal role in increased asthma incidence in the last 30 to 40 years\(^{260,261}\). Atopic diseases are associated with production of AA-derived...
eicosanoids such as PGD2, LTC4, LTD4 and LTE4. Also, PGE2 regulates the activities of macrophages and lymphocytes, inhibits the production of Th1-type cytokines (interferon (IFN)-γ, IL-2), regulates T-cell lymphocyte differentiation promoting the development of a Th2 phenotype46, and stimulates B-cells to produce immunoglobulin E (IgE) (ref.263). The protective effect of early perinatal exposure to marine LC n-3 PUFA against atopy development in the offspring has been demonstrated118,119. Also, a number of studies have been conducted investigating the possible therapeutic affects of fish oil on asthmatic adult patients. It has been reported that fish oil supplementation in patients with asthma has antiinflammatory effects264-266. Also, fish oil trials have shown beneficial effects on asthma clinical outcomes267. However, reviews on this field267,268 concluded that the evidence is inconsistent and that further studies are needed in order to provide strong evidence of the potent therapeutic effects of fish oil on asthma.

CONCLUSION

The importance of FAs as biocompounds can be demonstrated by their physiological roles, including lipid mediator production and involvement in gene expression. Although existing dietary reference values for fat intake vary between different nutrition bodies, all of them agree on a maximum intake of total fat of 30-35% TEI, a low intake of SFA and a higher intake of MFA. Regarding PUFA, it is essential to decrease n-6 PUFA and increase LC n-3 PUFA intake through oily fish consumption (1-2 portions/week). Public health policies promoting oily fish consumption should be formulated to ensure maternal consumption should be formulated to ensure maternal intake of at least 250-300 mg DHA/day. Increased intake of LC n-3 PUFA should also be promoted as secondary prevention of CHD because of their cardioprotective and antiinflammatory properties. Saturated FA and trans FA have a negative effect on CVD and metabolic disorders, whereas MFA may have a protective role. The beneficial effect of LC n-3 PUFA and the negative effect of SFA have been demonstrated in some types of cancer (pancreatic, breast, colon), but it should be further investigated in other types of cancer and in different stages. Critically ill patients and those suffering from chronic immune system disorders may benefit from decreased intake of n-6 and increased intake of n-3 PUFA. The effects of different types of fat on various conditions (pancreatic and liver function, cancer, asthma, mental health, growth and development) should be further investigated taking into account diet-gene interactions. This underlines the importance of nutrigenomics and environmental modifications for sustainable health and disease outcome.

ABBREVIATIONS

7-TM, 7-Tansmembrane- helix; AA, Arachidonic acid; AI, Adequate intake; ALA, α-Linolenic acid; AP, Activation protein; ARDS, Adult respiratory dis-

ACKNOWLEDGEMENT

This work is supported by the research project of the Ministry of Education, Youth and Sport (Czech Republic, MSM 0021620820 and MSM 0021620807).
REFERENCES


8. EFSA Panel on Dietetic Products, Nutrition and Allergens (NDA). Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA Journal 2010;8:1461.


57. NHMRC (National Health and Medical Research Council). Dietary Guidelines for Australian Adults. Canberra; 2003.
85. Houwelingen AC, Ham ECH, Hornstra G. The female docosahexaenoic acid status related to the number of completed pregnancies. Lipids 1999;34:S229.

Fatty acids as biocompounds: their role in human metabolism, health and disease – a review.
Part 2: fatty acid physiological roles and human applications in the field of human health and disease
Fatty acids as bio compounds: their role in human metabolism, health and disease - a review.

Part 2: fatty acid physiological roles and applications in human health and disease


175. Tholstrup T, Samman S. Postprandial lipoprotein(a) is affected differently by specific individual dietary fatty acids in healthy young men. J Nutr 2004;134:2350-5.


